nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—OPRD1—Amitriptyline—migraine	0.213	0.307	CbGbCtD
Naltrexone—OPRK1—Amitriptyline—migraine	0.178	0.256	CbGbCtD
Naltrexone—OPRM1—Amitriptyline—migraine	0.157	0.226	CbGbCtD
Naltrexone—ABCB1—Timolol—migraine	0.0449	0.0645	CbGbCtD
Naltrexone—ABCB1—Propranolol—migraine	0.04	0.0575	CbGbCtD
Naltrexone—ABCB1—Amitriptyline—migraine	0.0346	0.0497	CbGbCtD
Naltrexone—ABCB1—Verapamil—migraine	0.0274	0.0395	CbGbCtD
Naltrexone—Naloxone—ESR1—migraine	0.000573	1	CrCbGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1D—migraine	0.000333	0.0082	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1D—migraine	0.000328	0.00809	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—NPS—migraine	0.000325	0.00801	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—TAC1—migraine	0.000325	0.00801	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—EDNRA—migraine	0.00031	0.00764	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2B—migraine	0.000309	0.00763	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2B—migraine	0.000305	0.00752	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—SLC6A4—migraine	0.000298	0.00735	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CALCRL—migraine	0.000295	0.00727	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—RAMP1—migraine	0.000295	0.00727	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—HTR1B—migraine	0.000289	0.00713	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—HTR1D—migraine	0.000289	0.00712	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—TAC1—migraine	0.000285	0.00702	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—NPS—migraine	0.000285	0.00702	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1D—migraine	0.000281	0.00693	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—HTR1A—migraine	0.000278	0.00686	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—EDNRA—migraine	0.000272	0.0067	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—HTR2B—migraine	0.000268	0.00662	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—HTR1B—migraine	0.000268	0.00661	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2B—migraine	0.000261	0.00644	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—HTR1A—migraine	0.000258	0.00637	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—HTR1B—migraine	0.000253	0.00625	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—HTR1D—migraine	0.000253	0.00625	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2C—migraine	0.000249	0.00615	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—HTR1A—migraine	0.000244	0.00602	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—EDNRA—migraine	0.000243	0.00598	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—TAC1—migraine	0.000241	0.00594	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—NPS—migraine	0.000241	0.00594	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—HTR2B—migraine	0.000235	0.00581	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR1B—migraine	0.000235	0.0058	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR1B—migraine	0.00023	0.00567	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—EDNRA—migraine	0.00023	0.00566	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR1A—migraine	0.000226	0.00558	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—TGFBR2—migraine	0.000225	0.00554	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—RAMP1—migraine	0.000225	0.00554	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CALCRL—migraine	0.000225	0.00554	CbGpPWpGaD
Naltrexone—Cough—Valproic Acid—migraine	0.000222	0.000844	CcSEcCtD
Naltrexone—Dysgeusia—Timolol—migraine	0.000222	0.000843	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR1A—migraine	0.000221	0.00546	CbGpPWpGaD
Naltrexone—Urinary tract infection—Topiramate—migraine	0.000221	0.000839	CcSEcCtD
Naltrexone—Conjunctivitis—Topiramate—migraine	0.000221	0.000839	CcSEcCtD
Naltrexone—Nervousness—Timolol—migraine	0.00022	0.000836	CcSEcCtD
Naltrexone—Hypertension—Valproic Acid—migraine	0.00022	0.000835	CcSEcCtD
Naltrexone—Immune system disorder—Gabapentin—migraine	0.000219	0.000832	CcSEcCtD
Naltrexone—Mediastinal disorder—Gabapentin—migraine	0.000219	0.00083	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2C—migraine	0.000219	0.00539	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—HTR7—migraine	0.000218	0.00539	CbGpPWpGaD
Naltrexone—Diarrhoea—Propranolol—migraine	0.000218	0.000828	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—NPS—migraine	0.000218	0.00537	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—TAC1—migraine	0.000218	0.00537	CbGpPWpGaD
Naltrexone—Chills—Gabapentin—migraine	0.000218	0.000826	CcSEcCtD
Naltrexone—Myalgia—Valproic Acid—migraine	0.000217	0.000823	CcSEcCtD
Naltrexone—Arthralgia—Valproic Acid—migraine	0.000217	0.000823	CcSEcCtD
Naltrexone—Chest pain—Valproic Acid—migraine	0.000217	0.000823	CcSEcCtD
Naltrexone—Anxiety—Valproic Acid—migraine	0.000216	0.00082	CcSEcCtD
Naltrexone—Hypersensitivity—Verapamil—migraine	0.000216	0.00082	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—migraine	0.000215	0.000818	CcSEcCtD
Naltrexone—Epistaxis—Topiramate—migraine	0.000214	0.000814	CcSEcCtD
Naltrexone—Alopecia—Gabapentin—migraine	0.000214	0.000814	CcSEcCtD
Naltrexone—Discomfort—Valproic Acid—migraine	0.000214	0.000813	CcSEcCtD
Naltrexone—OPRM1—G alpha (i) signalling events—HTR1B—migraine	0.000214	0.00528	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HTR1D—migraine	0.000214	0.00528	CbGpPWpGaD
Naltrexone—Vision blurred—Timolol—migraine	0.000214	0.000811	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2C—migraine	0.000214	0.00527	CbGpPWpGaD
Naltrexone—Sinusitis—Topiramate—migraine	0.000213	0.00081	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—EDNRA—migraine	0.000213	0.00525	CbGpPWpGaD
Naltrexone—Mental disorder—Gabapentin—migraine	0.000213	0.000807	CcSEcCtD
Naltrexone—Dry mouth—Valproic Acid—migraine	0.000212	0.000805	CcSEcCtD
Naltrexone—Malnutrition—Gabapentin—migraine	0.000211	0.000802	CcSEcCtD
Naltrexone—Dizziness—Propranolol—migraine	0.000211	0.0008	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—FOS—migraine	0.000211	0.00519	CbGpPWpGaD
Naltrexone—Asthenia—Verapamil—migraine	0.00021	0.000799	CcSEcCtD
Naltrexone—Confusional state—Valproic Acid—migraine	0.00021	0.000796	CcSEcCtD
Naltrexone—Flatulence—Gabapentin—migraine	0.000208	0.00079	CcSEcCtD
Naltrexone—Oedema—Valproic Acid—migraine	0.000208	0.000789	CcSEcCtD
Naltrexone—Anaphylactic shock—Valproic Acid—migraine	0.000208	0.000789	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—EDNRA—migraine	0.000208	0.00513	CbGpPWpGaD
Naltrexone—Pruritus—Verapamil—migraine	0.000207	0.000787	CcSEcCtD
Naltrexone—Tension—Gabapentin—migraine	0.000207	0.000787	CcSEcCtD
Naltrexone—Angioedema—Timolol—migraine	0.000207	0.000787	CcSEcCtD
Naltrexone—Dysgeusia—Gabapentin—migraine	0.000207	0.000785	CcSEcCtD
Naltrexone—Infection—Valproic Acid—migraine	0.000207	0.000784	CcSEcCtD
Naltrexone—OPRM1—G alpha (i) signalling events—HTR1A—migraine	0.000206	0.00508	CbGpPWpGaD
Naltrexone—Nervousness—Gabapentin—migraine	0.000205	0.000779	CcSEcCtD
Naltrexone—Back pain—Gabapentin—migraine	0.000204	0.000775	CcSEcCtD
Naltrexone—Hepatitis—Topiramate—migraine	0.000204	0.000775	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—RAMP1—migraine	0.000204	0.00503	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CALCRL—migraine	0.000204	0.00503	CbGpPWpGaD
Naltrexone—Nervous system disorder—Valproic Acid—migraine	0.000204	0.000774	CcSEcCtD
Naltrexone—Syncope—Timolol—migraine	0.000203	0.000772	CcSEcCtD
Naltrexone—Hallucination—Topiramate—migraine	0.000203	0.000771	CcSEcCtD
Naltrexone—Muscle spasms—Gabapentin—migraine	0.000203	0.000771	CcSEcCtD
Naltrexone—Tachycardia—Valproic Acid—migraine	0.000203	0.00077	CcSEcCtD
Naltrexone—Vomiting—Propranolol—migraine	0.000203	0.000769	CcSEcCtD
Naltrexone—Pharyngitis—Topiramate—migraine	0.000203	0.000769	CcSEcCtD
Naltrexone—Skin disorder—Valproic Acid—migraine	0.000202	0.000767	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1B—migraine	0.000201	0.00497	CbGpPWpGaD
Naltrexone—Hyperhidrosis—Valproic Acid—migraine	0.000201	0.000763	CcSEcCtD
Naltrexone—Rash—Propranolol—migraine	0.000201	0.000763	CcSEcCtD
Naltrexone—Dermatitis—Propranolol—migraine	0.000201	0.000762	CcSEcCtD
Naltrexone—Diarrhoea—Verapamil—migraine	0.000201	0.000762	CcSEcCtD
Naltrexone—Connective tissue disorder—Topiramate—migraine	0.000201	0.000761	CcSEcCtD
Naltrexone—Palpitations—Timolol—migraine	0.0002	0.000761	CcSEcCtD
Naltrexone—Loss of consciousness—Timolol—migraine	0.000199	0.000757	CcSEcCtD
Naltrexone—Vision blurred—Gabapentin—migraine	0.000199	0.000755	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—HTR2B—migraine	0.000199	0.00491	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1B—migraine	0.000199	0.0049	CbGpPWpGaD
Naltrexone—Anorexia—Valproic Acid—migraine	0.000198	0.000752	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—migraine	0.000198	0.00488	CbGpPWpGaD
Naltrexone—Cough—Timolol—migraine	0.000198	0.000751	CcSEcCtD
Naltrexone—Tremor—Gabapentin—migraine	0.000198	0.000751	CcSEcCtD
Naltrexone—OPRK1—GPCR downstream signaling—CALCRL—migraine	0.000197	0.00486	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—RAMP1—migraine	0.000197	0.00486	CbGpPWpGaD
Naltrexone—Ill-defined disorder—Gabapentin—migraine	0.000196	0.000744	CcSEcCtD
Naltrexone—Hypertension—Timolol—migraine	0.000196	0.000743	CcSEcCtD
Naltrexone—Agitation—Gabapentin—migraine	0.000194	0.000737	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1A—migraine	0.000194	0.00478	CbGpPWpGaD
Naltrexone—Dizziness—Verapamil—migraine	0.000194	0.000736	CcSEcCtD
Naltrexone—Myalgia—Timolol—migraine	0.000193	0.000733	CcSEcCtD
Naltrexone—Arthralgia—Timolol—migraine	0.000193	0.000733	CcSEcCtD
Naltrexone—Chest pain—Timolol—migraine	0.000193	0.000733	CcSEcCtD
Naltrexone—Angioedema—Gabapentin—migraine	0.000193	0.000732	CcSEcCtD
Naltrexone—Anxiety—Timolol—migraine	0.000192	0.00073	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Timolol—migraine	0.000192	0.000728	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR7—migraine	0.000191	0.00472	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1A—migraine	0.000191	0.00472	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—NPS—migraine	0.000191	0.00471	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—TAC1—migraine	0.000191	0.00471	CbGpPWpGaD
Naltrexone—Discomfort—Timolol—migraine	0.000191	0.000724	CcSEcCtD
Naltrexone—Eye disorder—Topiramate—migraine	0.000191	0.000724	CcSEcCtD
Naltrexone—Malaise—Gabapentin—migraine	0.00019	0.000723	CcSEcCtD
Naltrexone—Tinnitus—Topiramate—migraine	0.00019	0.000722	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Valproic Acid—migraine	0.000189	0.000719	CcSEcCtD
Naltrexone—Cardiac disorder—Topiramate—migraine	0.000189	0.000719	CcSEcCtD
Naltrexone—Syncope—Gabapentin—migraine	0.000189	0.000719	CcSEcCtD
Naltrexone—Nausea—Propranolol—migraine	0.000189	0.000719	CcSEcCtD
Naltrexone—Dry mouth—Timolol—migraine	0.000189	0.000717	CcSEcCtD
Naltrexone—Insomnia—Valproic Acid—migraine	0.000188	0.000714	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2C—migraine	0.000187	0.00462	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR7—migraine	0.000187	0.00461	CbGpPWpGaD
Naltrexone—Paraesthesia—Valproic Acid—migraine	0.000187	0.000709	CcSEcCtD
Naltrexone—Palpitations—Gabapentin—migraine	0.000187	0.000708	CcSEcCtD
Naltrexone—Confusional state—Timolol—migraine	0.000187	0.000708	CcSEcCtD
Naltrexone—Vomiting—Verapamil—migraine	0.000186	0.000708	CcSEcCtD
Naltrexone—Loss of consciousness—Gabapentin—migraine	0.000186	0.000705	CcSEcCtD
Naltrexone—Dyspnoea—Valproic Acid—migraine	0.000185	0.000704	CcSEcCtD
Naltrexone—Angiopathy—Topiramate—migraine	0.000185	0.000703	CcSEcCtD
Naltrexone—Anaphylactic shock—Timolol—migraine	0.000185	0.000703	CcSEcCtD
Naltrexone—Oedema—Timolol—migraine	0.000185	0.000703	CcSEcCtD
Naltrexone—Rash—Verapamil—migraine	0.000185	0.000702	CcSEcCtD
Naltrexone—Somnolence—Valproic Acid—migraine	0.000185	0.000702	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2C—migraine	0.000185	0.00456	CbGpPWpGaD
Naltrexone—Dermatitis—Verapamil—migraine	0.000185	0.000701	CcSEcCtD
Naltrexone—Immune system disorder—Topiramate—migraine	0.000184	0.0007	CcSEcCtD
Naltrexone—Cough—Gabapentin—migraine	0.000184	0.0007	CcSEcCtD
Naltrexone—Mediastinal disorder—Topiramate—migraine	0.000184	0.000698	CcSEcCtD
Naltrexone—Infection—Timolol—migraine	0.000184	0.000698	CcSEcCtD
Naltrexone—Headache—Verapamil—migraine	0.000184	0.000697	CcSEcCtD
Naltrexone—Chills—Topiramate—migraine	0.000183	0.000695	CcSEcCtD
Naltrexone—Convulsion—Gabapentin—migraine	0.000183	0.000695	CcSEcCtD
Naltrexone—Hypertension—Gabapentin—migraine	0.000182	0.000692	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—EDNRA—migraine	0.000182	0.00449	CbGpPWpGaD
Naltrexone—Shock—Timolol—migraine	0.000182	0.000691	CcSEcCtD
Naltrexone—Nervous system disorder—Timolol—migraine	0.000182	0.000689	CcSEcCtD
Naltrexone—Decreased appetite—Valproic Acid—migraine	0.000181	0.000686	CcSEcCtD
Naltrexone—Alopecia—Topiramate—migraine	0.00018	0.000685	CcSEcCtD
Naltrexone—Arthralgia—Gabapentin—migraine	0.00018	0.000682	CcSEcCtD
Naltrexone—Myalgia—Gabapentin—migraine	0.00018	0.000682	CcSEcCtD
Naltrexone—Chest pain—Gabapentin—migraine	0.00018	0.000682	CcSEcCtD
Naltrexone—Skin disorder—Timolol—migraine	0.00018	0.000682	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—EDNRA—migraine	0.00018	0.00443	CbGpPWpGaD
Naltrexone—Gastrointestinal disorder—Valproic Acid—migraine	0.000179	0.000681	CcSEcCtD
Naltrexone—Fatigue—Valproic Acid—migraine	0.000179	0.00068	CcSEcCtD
Naltrexone—Anxiety—Gabapentin—migraine	0.000179	0.00068	CcSEcCtD
Naltrexone—Hyperhidrosis—Timolol—migraine	0.000179	0.000679	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—RAMP1—migraine	0.000179	0.00441	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CALCRL—migraine	0.000179	0.00441	CbGpPWpGaD
Naltrexone—Mental disorder—Topiramate—migraine	0.000179	0.000679	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—migraine	0.000179	0.000678	CcSEcCtD
Naltrexone—Pain—Valproic Acid—migraine	0.000178	0.000675	CcSEcCtD
Naltrexone—Constipation—Valproic Acid—migraine	0.000178	0.000675	CcSEcCtD
Naltrexone—Malnutrition—Topiramate—migraine	0.000178	0.000674	CcSEcCtD
Naltrexone—Discomfort—Gabapentin—migraine	0.000178	0.000674	CcSEcCtD
Naltrexone—Anorexia—Timolol—migraine	0.000176	0.00067	CcSEcCtD
Naltrexone—Dry mouth—Gabapentin—migraine	0.000176	0.000667	CcSEcCtD
Naltrexone—Flatulence—Topiramate—migraine	0.000175	0.000665	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—HTR1B—migraine	0.000175	0.00432	CbGpPWpGaD
Naltrexone—Tension—Topiramate—migraine	0.000174	0.000662	CcSEcCtD
Naltrexone—Nausea—Verapamil—migraine	0.000174	0.000661	CcSEcCtD
Naltrexone—Dysgeusia—Topiramate—migraine	0.000174	0.00066	CcSEcCtD
Naltrexone—Confusional state—Gabapentin—migraine	0.000174	0.00066	CcSEcCtD
Naltrexone—Nervousness—Topiramate—migraine	0.000173	0.000655	CcSEcCtD
Naltrexone—Oedema—Gabapentin—migraine	0.000172	0.000654	CcSEcCtD
Naltrexone—Anaphylactic shock—Gabapentin—migraine	0.000172	0.000654	CcSEcCtD
Naltrexone—Back pain—Topiramate—migraine	0.000172	0.000652	CcSEcCtD
Naltrexone—Feeling abnormal—Valproic Acid—migraine	0.000171	0.00065	CcSEcCtD
Naltrexone—Infection—Gabapentin—migraine	0.000171	0.00065	CcSEcCtD
Naltrexone—Muscle spasms—Topiramate—migraine	0.000171	0.000648	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—migraine	0.00017	0.0042	CbGpPWpGaD
Naltrexone—Gastrointestinal pain—Valproic Acid—migraine	0.00017	0.000645	CcSEcCtD
Naltrexone—Shock—Gabapentin—migraine	0.00017	0.000644	CcSEcCtD
Naltrexone—Nervous system disorder—Gabapentin—migraine	0.000169	0.000642	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Timolol—migraine	0.000169	0.00064	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—HTR1A—migraine	0.000168	0.00415	CbGpPWpGaD
Naltrexone—Tachycardia—Gabapentin—migraine	0.000168	0.000639	CcSEcCtD
Naltrexone—Vision blurred—Topiramate—migraine	0.000167	0.000636	CcSEcCtD
Naltrexone—Skin disorder—Gabapentin—migraine	0.000167	0.000635	CcSEcCtD
Naltrexone—Insomnia—Timolol—migraine	0.000167	0.000635	CcSEcCtD
Naltrexone—Hyperhidrosis—Gabapentin—migraine	0.000167	0.000632	CcSEcCtD
Naltrexone—Tremor—Topiramate—migraine	0.000166	0.000632	CcSEcCtD
Naltrexone—OPRM1—GPCR downstream signaling—CALCRL—migraine	0.000166	0.00411	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—RAMP1—migraine	0.000166	0.00411	CbGpPWpGaD
Naltrexone—Paraesthesia—Timolol—migraine	0.000166	0.000631	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—TAC1—migraine	0.000166	0.00409	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—NPS—migraine	0.000166	0.00409	CbGpPWpGaD
Naltrexone—Urticaria—Valproic Acid—migraine	0.000165	0.000627	CcSEcCtD
Naltrexone—Dyspnoea—Timolol—migraine	0.000165	0.000626	CcSEcCtD
Naltrexone—Ill-defined disorder—Topiramate—migraine	0.000165	0.000626	CcSEcCtD
Naltrexone—Somnolence—Timolol—migraine	0.000165	0.000625	CcSEcCtD
Naltrexone—Body temperature increased—Valproic Acid—migraine	0.000164	0.000624	CcSEcCtD
Naltrexone—Abdominal pain—Valproic Acid—migraine	0.000164	0.000624	CcSEcCtD
Naltrexone—Anorexia—Gabapentin—migraine	0.000164	0.000624	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR7—migraine	0.000164	0.00405	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1A—migraine	0.000164	0.00404	CbGpPWpGaD
Naltrexone—Agitation—Topiramate—migraine	0.000163	0.00062	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—HTR1D—migraine	0.000163	0.00403	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—HTR2C—migraine	0.000163	0.00401	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR7—migraine	0.000162	0.00399	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—TAC1—migraine	0.000161	0.00398	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—NPS—migraine	0.000161	0.00398	CbGpPWpGaD
Naltrexone—Decreased appetite—Timolol—migraine	0.000161	0.000611	CcSEcCtD
Naltrexone—Malaise—Topiramate—migraine	0.00016	0.000608	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Timolol—migraine	0.00016	0.000607	CcSEcCtD
Naltrexone—Fatigue—Timolol—migraine	0.00016	0.000606	CcSEcCtD
Naltrexone—Syncope—Topiramate—migraine	0.000159	0.000605	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2C—migraine	0.000158	0.0039	CbGpPWpGaD
Naltrexone—Pain—Timolol—migraine	0.000158	0.000601	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—EDNRA—migraine	0.000158	0.0039	CbGpPWpGaD
Naltrexone—Musculoskeletal discomfort—Gabapentin—migraine	0.000157	0.000596	CcSEcCtD
Naltrexone—Palpitations—Topiramate—migraine	0.000157	0.000596	CcSEcCtD
Naltrexone—Loss of consciousness—Topiramate—migraine	0.000156	0.000593	CcSEcCtD
Naltrexone—Insomnia—Gabapentin—migraine	0.000156	0.000592	CcSEcCtD
Naltrexone—Cough—Topiramate—migraine	0.000155	0.000589	CcSEcCtD
Naltrexone—Paraesthesia—Gabapentin—migraine	0.000155	0.000587	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—EDNRA—migraine	0.000154	0.0038	CbGpPWpGaD
Naltrexone—Convulsion—Topiramate—migraine	0.000154	0.000584	CcSEcCtD
Naltrexone—Dyspnoea—Gabapentin—migraine	0.000154	0.000583	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—HTR1B—migraine	0.000153	0.00378	CbGpPWpGaD
Naltrexone—Hypertension—Topiramate—migraine	0.000153	0.000582	CcSEcCtD
Naltrexone—Somnolence—Gabapentin—migraine	0.000153	0.000582	CcSEcCtD
Naltrexone—Hypersensitivity—Valproic Acid—migraine	0.000153	0.000581	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2A—migraine	0.000153	0.00377	CbGpPWpGaD
Naltrexone—Feeling abnormal—Timolol—migraine	0.000153	0.000579	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—CALCA—migraine	0.000152	0.00376	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—HTR2B—migraine	0.000152	0.00374	CbGpPWpGaD
Naltrexone—Gastrointestinal pain—Timolol—migraine	0.000151	0.000574	CcSEcCtD
Naltrexone—Arthralgia—Topiramate—migraine	0.000151	0.000574	CcSEcCtD
Naltrexone—Myalgia—Topiramate—migraine	0.000151	0.000574	CcSEcCtD
Naltrexone—Chest pain—Topiramate—migraine	0.000151	0.000574	CcSEcCtD
Naltrexone—OPRM1—Signaling by GPCR—CALCRL—migraine	0.000151	0.00373	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RAMP1—migraine	0.000151	0.00373	CbGpPWpGaD
Naltrexone—Anxiety—Topiramate—migraine	0.000151	0.000572	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Topiramate—migraine	0.00015	0.00057	CcSEcCtD
Naltrexone—Decreased appetite—Gabapentin—migraine	0.00015	0.000569	CcSEcCtD
Naltrexone—Discomfort—Topiramate—migraine	0.000149	0.000567	CcSEcCtD
Naltrexone—Asthenia—Valproic Acid—migraine	0.000149	0.000566	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Gabapentin—migraine	0.000149	0.000565	CcSEcCtD
Naltrexone—Fatigue—Gabapentin—migraine	0.000149	0.000564	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—HTR1D—migraine	0.000148	0.00366	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—TRPM8—migraine	0.000148	0.00365	CbGpPWpGaD
Naltrexone—Dry mouth—Topiramate—migraine	0.000148	0.000562	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—HTR1A—migraine	0.000148	0.00364	CbGpPWpGaD
Naltrexone—Constipation—Gabapentin—migraine	0.000147	0.000559	CcSEcCtD
Naltrexone—Pain—Gabapentin—migraine	0.000147	0.000559	CcSEcCtD
Naltrexone—Pruritus—Valproic Acid—migraine	0.000147	0.000558	CcSEcCtD
Naltrexone—Urticaria—Timolol—migraine	0.000147	0.000558	CcSEcCtD
Naltrexone—Abdominal pain—Timolol—migraine	0.000146	0.000555	CcSEcCtD
Naltrexone—Body temperature increased—Timolol—migraine	0.000146	0.000555	CcSEcCtD
Naltrexone—Confusional state—Topiramate—migraine	0.000146	0.000555	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—NPS—migraine	0.000145	0.00359	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—TAC1—migraine	0.000145	0.00359	CbGpPWpGaD
Naltrexone—Oedema—Topiramate—migraine	0.000145	0.00055	CcSEcCtD
Naltrexone—Infection—Topiramate—migraine	0.000144	0.000547	CcSEcCtD
Naltrexone—OPRK1—GPCR downstream signaling—HTR1D—migraine	0.000143	0.00353	CbGpPWpGaD
Naltrexone—Shock—Topiramate—migraine	0.000143	0.000542	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—HTR2C—migraine	0.000143	0.00352	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—HTR7—migraine	0.000142	0.00351	CbGpPWpGaD
Naltrexone—Diarrhoea—Valproic Acid—migraine	0.000142	0.00054	CcSEcCtD
Naltrexone—Nervous system disorder—Topiramate—migraine	0.000142	0.00054	CcSEcCtD
Naltrexone—Feeling abnormal—Gabapentin—migraine	0.000142	0.000539	CcSEcCtD
Naltrexone—Tachycardia—Topiramate—migraine	0.000142	0.000537	CcSEcCtD
Naltrexone—Gastrointestinal pain—Gabapentin—migraine	0.000141	0.000535	CcSEcCtD
Naltrexone—Skin disorder—Topiramate—migraine	0.000141	0.000535	CcSEcCtD
Naltrexone—Hyperhidrosis—Topiramate—migraine	0.00014	0.000532	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—EDNRA—migraine	0.000139	0.00342	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR7—migraine	0.000139	0.00342	CbGpPWpGaD
Naltrexone—Anorexia—Topiramate—migraine	0.000138	0.000525	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—HTR2B—migraine	0.000138	0.0034	CbGpPWpGaD
Naltrexone—Dizziness—Valproic Acid—migraine	0.000137	0.000522	CcSEcCtD
Naltrexone—Urticaria—Gabapentin—migraine	0.000137	0.00052	CcSEcCtD
Naltrexone—Hypersensitivity—Timolol—migraine	0.000136	0.000518	CcSEcCtD
Naltrexone—Body temperature increased—Gabapentin—migraine	0.000136	0.000517	CcSEcCtD
Naltrexone—Abdominal pain—Gabapentin—migraine	0.000136	0.000517	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—migraine	0.000134	0.00331	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CALCA—migraine	0.000134	0.00329	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR2B—migraine	0.000133	0.00328	CbGpPWpGaD
Naltrexone—Asthenia—Timolol—migraine	0.000133	0.000504	CcSEcCtD
Naltrexone—Vomiting—Valproic Acid—migraine	0.000132	0.000502	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Topiramate—migraine	0.000132	0.000501	CcSEcCtD
Naltrexone—Insomnia—Topiramate—migraine	0.000131	0.000498	CcSEcCtD
Naltrexone—Rash—Valproic Acid—migraine	0.000131	0.000498	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—migraine	0.000131	0.00323	CbGpPWpGaD
Naltrexone—Dermatitis—Valproic Acid—migraine	0.000131	0.000497	CcSEcCtD
Naltrexone—Pruritus—Timolol—migraine	0.000131	0.000497	CcSEcCtD
Naltrexone—Headache—Valproic Acid—migraine	0.00013	0.000494	CcSEcCtD
Naltrexone—Paraesthesia—Topiramate—migraine	0.00013	0.000494	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—HTR1D—migraine	0.00013	0.00321	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HTR1B—migraine	0.00013	0.0032	CbGpPWpGaD
Naltrexone—Dyspnoea—Topiramate—migraine	0.000129	0.000491	CcSEcCtD
Naltrexone—Somnolence—Topiramate—migraine	0.000129	0.000489	CcSEcCtD
Naltrexone—Hypersensitivity—Gabapentin—migraine	0.000127	0.000482	CcSEcCtD
Naltrexone—Diarrhoea—Timolol—migraine	0.000127	0.000481	CcSEcCtD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—FOS—migraine	0.000127	0.00312	CbGpPWpGaD
Naltrexone—Decreased appetite—Topiramate—migraine	0.000126	0.000478	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Topiramate—migraine	0.000125	0.000475	CcSEcCtD
Naltrexone—Fatigue—Topiramate—migraine	0.000125	0.000475	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—HTR7—migraine	0.000125	0.00308	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HTR1A—migraine	0.000125	0.00308	CbGpPWpGaD
Naltrexone—Constipation—Topiramate—migraine	0.000124	0.000471	CcSEcCtD
Naltrexone—Pain—Topiramate—migraine	0.000124	0.000471	CcSEcCtD
Naltrexone—Asthenia—Gabapentin—migraine	0.000124	0.000469	CcSEcCtD
Naltrexone—Nausea—Valproic Acid—migraine	0.000123	0.000469	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—NPS—migraine	0.000123	0.00303	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—TAC1—migraine	0.000123	0.00303	CbGpPWpGaD
Naltrexone—Dizziness—Timolol—migraine	0.000122	0.000465	CcSEcCtD
Naltrexone—Pruritus—Gabapentin—migraine	0.000122	0.000463	CcSEcCtD
Naltrexone—OPRM1—GPCR downstream signaling—HTR1D—migraine	0.000121	0.00298	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR2B—migraine	0.000121	0.00298	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HTR2C—migraine	0.000121	0.00297	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CALCRL—migraine	0.00012	0.00297	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAMP1—migraine	0.00012	0.00297	CbGpPWpGaD
Naltrexone—Feeling abnormal—Topiramate—migraine	0.000119	0.000454	CcSEcCtD
Naltrexone—Gastrointestinal pain—Topiramate—migraine	0.000119	0.00045	CcSEcCtD
Naltrexone—Diarrhoea—Gabapentin—migraine	0.000118	0.000448	CcSEcCtD
Naltrexone—Vomiting—Timolol—migraine	0.000118	0.000447	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—EDNRA—migraine	0.000117	0.00289	CbGpPWpGaD
Naltrexone—Rash—Timolol—migraine	0.000117	0.000443	CcSEcCtD
Naltrexone—Dermatitis—Timolol—migraine	0.000117	0.000443	CcSEcCtD
Naltrexone—Headache—Timolol—migraine	0.000116	0.00044	CcSEcCtD
Naltrexone—Urticaria—Topiramate—migraine	0.000115	0.000437	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—migraine	0.000115	0.00283	CbGpPWpGaD
Naltrexone—Body temperature increased—Topiramate—migraine	0.000115	0.000435	CcSEcCtD
Naltrexone—Abdominal pain—Topiramate—migraine	0.000115	0.000435	CcSEcCtD
Naltrexone—Dizziness—Gabapentin—migraine	0.000114	0.000433	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—migraine	0.000113	0.0028	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CALCA—migraine	0.000113	0.00278	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR2B—migraine	0.000112	0.00277	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ATP1A3—migraine	0.000112	0.00277	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ATP1A2—migraine	0.000112	0.00277	CbGpPWpGaD
Naltrexone—Nausea—Timolol—migraine	0.00011	0.000417	CcSEcCtD
Naltrexone—OPRM1—Signaling by GPCR—HTR1D—migraine	0.00011	0.00271	CbGpPWpGaD
Naltrexone—Vomiting—Gabapentin—migraine	0.00011	0.000416	CcSEcCtD
Naltrexone—Rash—Gabapentin—migraine	0.000109	0.000413	CcSEcCtD
Naltrexone—Dermatitis—Gabapentin—migraine	0.000109	0.000412	CcSEcCtD
Naltrexone—Headache—Gabapentin—migraine	0.000108	0.00041	CcSEcCtD
Naltrexone—Hypersensitivity—Topiramate—migraine	0.000107	0.000406	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—CALCRL—migraine	0.000106	0.00261	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAMP1—migraine	0.000106	0.00261	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HTR7—migraine	0.000106	0.0026	CbGpPWpGaD
Naltrexone—Asthenia—Topiramate—migraine	0.000104	0.000395	CcSEcCtD
Naltrexone—Pruritus—Topiramate—migraine	0.000103	0.000389	CcSEcCtD
Naltrexone—Nausea—Gabapentin—migraine	0.000102	0.000389	CcSEcCtD
Naltrexone—OPRM1—Signaling by GPCR—HTR2B—migraine	0.000102	0.00252	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—HTR2A—migraine	9.98e-05	0.00246	CbGpPWpGaD
Naltrexone—Diarrhoea—Topiramate—migraine	9.92e-05	0.000377	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—HTR1B—migraine	9.89e-05	0.00244	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—migraine	9.71e-05	0.0024	CbGpPWpGaD
Naltrexone—Dizziness—Topiramate—migraine	9.59e-05	0.000364	CcSEcCtD
Naltrexone—ABCB1—Transmembrane transport of small molecules—HTR3A—migraine	9.53e-05	0.00235	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—HTR1A—migraine	9.52e-05	0.00235	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—TAC1—migraine	9.37e-05	0.00231	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—NPS—migraine	9.37e-05	0.00231	CbGpPWpGaD
Naltrexone—Vomiting—Topiramate—migraine	9.22e-05	0.00035	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—HTR2C—migraine	9.19e-05	0.00227	CbGpPWpGaD
Naltrexone—Rash—Topiramate—migraine	9.14e-05	0.000347	CcSEcCtD
Naltrexone—Dermatitis—Topiramate—migraine	9.13e-05	0.000347	CcSEcCtD
Naltrexone—Headache—Topiramate—migraine	9.08e-05	0.000345	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—HTR1B—migraine	8.98e-05	0.00221	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—EDNRA—migraine	8.94e-05	0.00221	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CALCRL—migraine	8.93e-05	0.0022	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAMP1—migraine	8.93e-05	0.0022	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR1D—migraine	8.75e-05	0.00216	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—HTR2A—migraine	8.75e-05	0.00216	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR1B—migraine	8.67e-05	0.00214	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HTR1A—migraine	8.64e-05	0.00213	CbGpPWpGaD
Naltrexone—Nausea—Topiramate—migraine	8.61e-05	0.000327	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—CALCA—migraine	8.61e-05	0.00212	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—TAC1—migraine	8.51e-05	0.0021	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—NPS—migraine	8.51e-05	0.0021	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HTR2C—migraine	8.35e-05	0.00206	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR1A—migraine	8.35e-05	0.00206	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CACNA1A—migraine	8.28e-05	0.00204	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—TAC1—migraine	8.22e-05	0.00203	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—NPS—migraine	8.22e-05	0.00203	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR2B—migraine	8.14e-05	0.00201	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EDNRA—migraine	8.12e-05	0.002	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR2C—migraine	8.06e-05	0.00199	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—HTR7—migraine	8.05e-05	0.00199	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—migraine	8e-05	0.00197	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR1B—migraine	7.87e-05	0.00194	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—EDNRA—migraine	7.84e-05	0.00193	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CALCA—migraine	7.82e-05	0.00193	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR1D—migraine	7.68e-05	0.00189	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR1A—migraine	7.58e-05	0.00187	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CALCA—migraine	7.55e-05	0.00186	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—TAC1—migraine	7.46e-05	0.00184	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—NPS—migraine	7.46e-05	0.00184	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HTR2A—migraine	7.39e-05	0.00182	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR1B—migraine	7.33e-05	0.00181	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR2C—migraine	7.32e-05	0.00181	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HTR7—migraine	7.31e-05	0.0018	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LRP1—migraine	7.17e-05	0.00177	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR2B—migraine	7.14e-05	0.00176	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EDNRA—migraine	7.12e-05	0.00176	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR7—migraine	7.06e-05	0.00174	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR1A—migraine	7.05e-05	0.00174	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—TAC1—migraine	6.95e-05	0.00171	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—NPS—migraine	6.95e-05	0.00171	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CALCA—migraine	6.85e-05	0.00169	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR2C—migraine	6.81e-05	0.00168	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR1B—migraine	6.65e-05	0.00164	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—EDNRA—migraine	6.63e-05	0.00163	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR1D—migraine	6.49e-05	0.0016	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR7—migraine	6.41e-05	0.00158	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR1A—migraine	6.4e-05	0.00158	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CALCA—migraine	6.38e-05	0.00157	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—TAC1—migraine	6.31e-05	0.00156	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—NPS—migraine	6.31e-05	0.00156	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LRP1—migraine	6.28e-05	0.00155	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR2C—migraine	6.19e-05	0.00153	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR2B—migraine	6.03e-05	0.00149	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EDNRA—migraine	6.02e-05	0.00148	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—migraine	6e-05	0.00148	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR7—migraine	5.97e-05	0.00147	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—migraine	5.89e-05	0.00145	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CALCA—migraine	5.79e-05	0.00143	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—HTR2A—migraine	5.64e-05	0.00139	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH4—migraine	5.5e-05	0.00136	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR7—migraine	5.42e-05	0.00134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LRP1—migraine	5.31e-05	0.00131	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR1B—migraine	5.3e-05	0.00131	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HTR2A—migraine	5.12e-05	0.00126	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR1A—migraine	5.11e-05	0.00126	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PGR—migraine	5.03e-05	0.00124	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TAC1—migraine	5.03e-05	0.00124	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NPS—migraine	5.03e-05	0.00124	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR2A—migraine	4.94e-05	0.00122	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR2C—migraine	4.93e-05	0.00122	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH4—migraine	4.82e-05	0.00119	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EDNRA—migraine	4.8e-05	0.00118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH3—migraine	4.67e-05	0.00115	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR1B—migraine	4.65e-05	0.00115	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CALCA—migraine	4.62e-05	0.00114	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR2A—migraine	4.49e-05	0.00111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR1A—migraine	4.48e-05	0.0011	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NPS—migraine	4.41e-05	0.00109	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PGR—migraine	4.41e-05	0.00109	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TAC1—migraine	4.41e-05	0.00109	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR2C—migraine	4.32e-05	0.00107	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR7—migraine	4.32e-05	0.00107	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EDNRA—migraine	4.21e-05	0.00104	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR2A—migraine	4.18e-05	0.00103	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH3—migraine	4.1e-05	0.00101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH4—migraine	4.07e-05	0.001	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CALCA—migraine	4.05e-05	0.000999	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR1B—migraine	3.93e-05	0.00097	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CACNA1A—migraine	3.8e-05	0.000936	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR2A—migraine	3.79e-05	0.000936	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR7—migraine	3.79e-05	0.000934	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR1A—migraine	3.78e-05	0.000933	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TAC1—migraine	3.73e-05	0.000919	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PGR—migraine	3.73e-05	0.000919	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NPS—migraine	3.73e-05	0.000919	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFBR2—migraine	3.72e-05	0.000917	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR2C—migraine	3.65e-05	0.000901	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EDNRA—migraine	3.55e-05	0.000877	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH3—migraine	3.46e-05	0.000854	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CALCA—migraine	3.42e-05	0.000844	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFBR2—migraine	3.26e-05	0.000804	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR7—migraine	3.2e-05	0.000789	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR2A—migraine	3.02e-05	0.000746	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—migraine	2.91e-05	0.000717	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFBR2—migraine	2.76e-05	0.00068	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—migraine	2.74e-05	0.000675	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ESR1—migraine	2.68e-05	0.000662	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR2A—migraine	2.65e-05	0.000654	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—migraine	2.35e-05	0.000581	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR2A—migraine	2.24e-05	0.000553	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—migraine	1.99e-05	0.000491	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—migraine	1.26e-05	0.00031	CbGpPWpGaD
